Since the 2013 decision in the Myriad case, which invalidated some patent claims on isolated sequences of two genes relevant in some cases of breast cancer, there have been two major actions taking place. Following the decision the Patent and Trademark Office (USPTO) has been working on guidance for potential patent applicants working with products of nature. The latest guidance memo was released in December (H/T ScienceInsider), and the USPTO is taking comments until March 15. There has been a back and forth with the biomedical research community, which has argued that the initial guidance (from March 2014) went further than the Supreme Court intended. The USPTO has made changes in response.
The other post-Supreme Court thrust has involved lawsuits by Myriad Genetics against companies developing their own genetic tests for the breast cancer genes where Myriad held patent claims. The company was protecting its market share and investment through the lawsuits and the settlement terms it has been able to reach.. ScienceInsider is reporting that many of the remaining cases have settled and The New York Times has noted that Myriad is working to address the remaining cases.